AU2001218083A1 - Ace inhibitor-vasopressin antagonist combinations - Google Patents

Ace inhibitor-vasopressin antagonist combinations

Info

Publication number
AU2001218083A1
AU2001218083A1 AU2001218083A AU1808301A AU2001218083A1 AU 2001218083 A1 AU2001218083 A1 AU 2001218083A1 AU 2001218083 A AU2001218083 A AU 2001218083A AU 1808301 A AU1808301 A AU 1808301A AU 2001218083 A1 AU2001218083 A1 AU 2001218083A1
Authority
AU
Australia
Prior art keywords
ace inhibitor
vasopressin antagonist
antagonist combinations
combinations
vasopressin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001218083A
Inventor
Millton Lethan Pressler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2001218083A1 publication Critical patent/AU2001218083A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combinations of ACE inhibitors and vasopressin antagonists are useful to slow and reverse the process of ventricular dilation, and CHF in mammals.
AU2001218083A 2000-01-26 2000-11-30 Ace inhibitor-vasopressin antagonist combinations Abandoned AU2001218083A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17816900P 2000-01-26 2000-01-26
US60/178,169 2000-01-26
PCT/US2000/032569 WO2001054677A2 (en) 2000-01-26 2000-11-30 Ace inhibitor-vasopressin antagonist combinations

Publications (1)

Publication Number Publication Date
AU2001218083A1 true AU2001218083A1 (en) 2001-08-07

Family

ID=22651476

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001218083A Abandoned AU2001218083A1 (en) 2000-01-26 2000-11-30 Ace inhibitor-vasopressin antagonist combinations

Country Status (10)

Country Link
EP (1) EP1253945B1 (en)
JP (1) JP2003521496A (en)
AT (1) ATE341342T1 (en)
AU (1) AU2001218083A1 (en)
BR (1) BR0017074A (en)
CA (1) CA2397244C (en)
DE (1) DE60031171T2 (en)
ES (1) ES2272341T3 (en)
MX (1) MXPA02006352A (en)
WO (1) WO2001054677A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI322689B (en) 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
CN101854932A (en) * 2007-11-07 2010-10-06 詹森药业有限公司 Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271747A (en) * 1985-06-12 1990-07-17 David M. Floyd Benzazepines derivatives
CA1271748C (en) * 1985-12-12 1990-07-17 Benzazepine derivatives
IL90189A0 (en) * 1988-06-01 1989-12-15 Squibb & Sons Inc Pharmaceutical compositions containing a benzazepine-type calcium channel blocker
EP0365134A1 (en) * 1988-09-16 1990-04-25 Smithkline Beecham Corporation Synergistic compositions of renal dopaminergic agent and angiotensin converting enzyme inhibitors
IT1254314B (en) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE AND ACYL-CARNITINE ASSOCIATION WITH ACE-INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
PL177738B1 (en) * 1993-07-21 2000-01-31 Yamanouchi Pharma Co Ltd Condensed benzazepine derivatives, and their pharmaceutical compounds

Also Published As

Publication number Publication date
ES2272341T3 (en) 2007-05-01
CA2397244C (en) 2009-11-17
EP1253945A2 (en) 2002-11-06
CA2397244A1 (en) 2001-08-02
WO2001054677A2 (en) 2001-08-02
ATE341342T1 (en) 2006-10-15
DE60031171T2 (en) 2007-08-23
EP1253945B1 (en) 2006-10-04
DE60031171D1 (en) 2006-11-16
BR0017074A (en) 2002-12-03
JP2003521496A (en) 2003-07-15
MXPA02006352A (en) 2002-11-29
WO2001054677A9 (en) 2003-06-12
WO2001054677A3 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
IL152916A0 (en) Heteroaryl-phenyl heterobicyclic factor xa inhibitors
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
NO20054369L (en) Use of an IBAT inhibitor for the treatment and prophylaxis of constipation
WO2001085196A3 (en) Cxcr4 antagonist treatment of hematopoietic cells
AU5414000A (en) Compounds
WO2004096798A3 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
MXPA02011411A (en) Serine protease inhibitors.
AU8677801A (en) Inhibitors of alpha4 mediated cell adhesion
TR200103216T2 (en) Pyrimidinone compositions
WO2001076574A3 (en) Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
TR200102711T2 (en) Anticonvulsant derivatives for use in the treatment of crisis headaches
FI955315A (en) Inhibitors of HIV protease, useful in the treatment of AIDS
AU2001274220A1 (en) Serine protease inhibitors
EA200400734A1 (en) METHOD AND COMPOSITION FOR POTENTIATING OPIATIVE ANALGETIC ACTION
UY25321A1 (en) MMP ACE-INHIBITOR INHIBITOR COMBINATIONS
WO1999020260A3 (en) The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
GB0030303D0 (en) Compounds
GB0030306D0 (en) Compounds
GB0003025D0 (en) Novel compounds
WO2000040583A3 (en) Imidazo[4,5-c]-pyridine-4-on-derivatives
NO20031525D0 (en) Chemokine mutants in the treatment of multiple sclerosis
AU2001218083A1 (en) Ace inhibitor-vasopressin antagonist combinations
TR200200169T2 (en) The use of IL-18 inhibitors.
DE60108495D1 (en) Thrombin inhibitoren
UY26648A1 (en) VASOPEPTIDASE INHIBITORS TO TREAT ISOLATED SYSTOLIC HYPERTENSION